The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effects of dose modification of eribulin mesylate in patients with locally recurrent or metastatic breast cancer.
Claudio Faria
Employment or Leadership Position - Eisai
Xuan Li
Employment or Leadership Position - Eisai
Annette Powers
Employment or Leadership Position - Eisai
Linda T. Vahdat
No relevant relationships to disclose